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Abstract 
BACKGROUND AND PURPOSE 
Heat sensitive transient receptor potential vanilloid (TRPV) channels are expressed in various 
epithelial tissues regulating, among else, barrier functions. Their expression is well established 
in the distal nephron; however, we have no data about their presence in podocytes. Since 
podocytes are indispensable in the formation of the glomerular filtration barrier, we 
investigated the presence and function of Ca2+-permeable TRPV1-4 channels in human 
podocyte cultures. 
EXPERIMENTAL APPROACH 
The expression of TRPV1-4 was investigated at protein (immunocytochemistry, western blot) 
and mRNA (Q-PCR) level in a conditionally immortalized human podocyte cell line. The 
channel functionality was assessed by measuring intracellular Ca2+ concentration using fluo-4 
Ca2+-indicator dye and patch clamp electrophysiology upon applying various activators and 
inhibitors. 
KEY RESULTS 
Thermosensitive TRP channels were expressed in podocytes. The TRPV1 specific agonists 
capsaicin and resiniferatoxin did not induce any alteration in the intracellular Ca2+ 
concentration. Cannabidiol, an activator of TRPV2 and TRPV4 induced moderate Ca2+-
influxes which were inhibited by both tranilast and HC067047, blockers of TRPV2 and 
TRPV4, respectively. The TRPV4-specific agonists GSK1016790A and 4α-Phorbol 12,13-
didecanoate resulted robust Ca2+-signals which were abolished in the presence of HC067047. 
Non-specific agonists of TRPV3 induced marked Ca2+ transients. However, TRPV3 blockers, 
ruthenium red and isopentenyl diphosphate only partially inhibited the responses and TRPV3 
silencing was ineffective suggesting remarkable off-target effects of the compounds. 
CONCLUSION AND IMPLICATIONS 
Our results indicate the functional presence of TRPV4 and other thermosensitive TRPV 
channels in human podocytes and raise the possibility of their involvement in the regulation of 
glomerular filtration barrier. 
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Introduction 
Among voltage gated ion channels, transient receptor potential (TRP) ion channels form 
a heterogeneous group with diverse functions. They are sensitive for various physical stimuli, 
like osmotic challenges, mechanical stimulation, changes of membrane potential or 
environmental temperature. Therefore, they are generally considered as multimodal cellular 
sensors. Moreover, TRP channels possess marked chemosensitivity, as well. They can be 
activated or inhibited by several endogenous or exogenous chemical ligands opening a huge 
field for potential pharmacological interventions (Nilius and Szallasi, 2014). Amongst TRP 
channels, the thermosensitive members are the most pursued drug targets especially because 
of their vital role in several sensory functions (Moran et al., 2011). However, thermoTRPs, 
especially the heat sensitive members of the vanilloid (TRPV) subfamily play an emerging role 
in epithelial biology and barrier functions, as well (Moran et al., 2011; Nilius and Szallasi, 
2014). They are widely expressed in the outer and inner linings of the human body, like in the 
skin (Tóth et al., 2014), airway epithelia (Grace et al., 2014), endothelium (Earley and Brayden, 
2015) or reabsorbing epithelium of kidney tubules (Kassmann et al., 2013). 
The expression of several TRP channels is known along the nephron playing important 
(patho)physiological role in kidney functions (Woudenberg-Vrenken et al., 2009). TRPV5/6 
and TRPM6 expressed in the apical membrane of distal tubule epithelium play an essential role 
in ion homeostasis via ensuring physiological reabsorption of Ca2+ and Mg2+, respectively 
(Dimke et al., 2011). Mutations in TRPP1/2 complex serve as etiological factors in the 
development of polycystic kidney disease (Retailleau and Duprat, 2014; Tóth and Nilius, 
2015). TRPC6 regulates podocytes’ function influencing the integrity of the glomerular 
filtration barrier and playing etiological role in different proteinuric diseases, among else 
familial focal segmental glomerulosclerosis (FSGS) (Dryer and Reiser, 2010; Tóth and Nilius, 
2015).  
Regarding the heat sensitive TRPV channels, TRPV4 is expressed in various segments 
of the urogenital tract, involving distal tubules of the kidney, and it was found playing an 
important role in cell junction and barrier formation (Janssen et al., 2016). The presence of 
TRPV1 was also shown in the tubules of the renal cortex and medulla as well as in the wall of 
the renal pelvis (Feng et al., 2008; Kassmann et al., 2013). Moreover, both TRPV1 and TRPV4 
can influence endothelial barrier functions (Alvarez et al., 2006; Yang et al., 2010) which can 
affect the vascular side of the glomerular filtration barrier. However, we do not bare any data 
about the expression of these channels in the other component of the glomerular filtration 
barrier, i.e. podocytes of the Bowman’s capsule. Therefore, in the current study, we aimed at 
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investigating the molecular expression and functionality of heat sensitive TRPV1-4 channels 
in human podocytes using a conditionally immortalized human podocyte cell culture system.  
  
 
Methods 
 
Cell culturing 
Human podocyte cell line provided by Prof. Hermann Pavenstädt (University Hospital of 
Münster, Münster, Germany) was established and cultured as described previously (Saleem et 
al., 2002; Ambrus et al., 2015). In brief, cells were cultured in “permissive” condition in RPMI 
medium (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% fetal bovine 
serum, (Invitrogen, Paisley, UK), 50 U/ml penicillin, 50 μg/ml streptomycin, 1.25 μg/ml 
Fungizone (both from PPA Laboratories GmbH) and insulin-transferrin-selenium (1:100; 
Invitrogen) at 33°C to maintain proliferation. Differentiation was induced by switching to 
“non-permissive” condition transferring cells to 37°C and kept in culture for 7 days. The 
process of differentiation was evaluated using Western blotting and immunocytochemistry by 
determining the expression of the podocyte-specific marker podocin and the differentiation 
marker synaptopodin as show in our previous work (Ambrus et al., 2015). HEK293T cells were 
cultured in DMEM medium (PAA Laboratories GmbH) supplemented with 10% fetal bovine 
serum, (Invitrogen), 50 U/ml penicillin, 50 μg/ml streptomycin, 1.25 μg/ml Fungizone (both 
from PPA Laboratories GmbH) and non-essential aminoacids (Sigma-Aldrich, St Louis, MO, 
USA). 
 
Antibodies 
The following primary antibodies were employed for immunocytochemistry: mouse anti-
human TRPV1, rabbit anti-human TRPV4 (both from Novus Biologicals, Littleton, CO, USA), 
rabbit anti-human TRPV2, rabbit anti-human TRPV3 (both from Abcam, Cambridge, UK). For 
Western blotting we used goat anti-human TRPV1 (Santa Cruz, Heidelberg, Germany), rabbit 
anti-human TRPV3, rabbit anti-human TRPV4 (Alomone Labs, Jerusalem, Israel), rabbit anti-
human TRPV2 and rabbit-anti-human β-actin (Sigma-Aldrich). 
 
Immunocytochemistry 
Human podocytes were cultured and differentiated on glass coverslips in 6-well plates, were 
fixed by 4% paraformaldehyde containing phosphate-buffered saline (PBS; 115 mM NaCl, 20 
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mM Na2PO4, pH 7.4; all from Sigma-Aldrich) for 10 min at room temperature, and 
permeabilized by 0.3% Triton-X-100 (Sigma-Aldrich) in PBS for 10 min. Following 30 min 
incubation in blocking solution (0.3% Triton-X-100 and 1% BSA containing PBS; both from 
Sigma-Aldrich) at room temperature, cells were probed with the previously mentioned primary 
antibodies raised against human TRPV1 (1:50), TRPV4 (1:50), TRPV2 (1:100) and TRPV3 
(1:100) overnight at 4°C. Following appropriate washing in PBS, coverslips were incubated 
with Alexa-488®-conjugated goat-anti-mouse and goat-anti-rabbit secondary antibodies 
(1:200, Invitrogen) for 1 hour at room temperature. Nuclei were counterstained with 4',6-
diamidino-2-phenylindole (DAPI, Vector Laboratories, Peterborough, UK). Negative control 
cells were stained omitting the primary antibodies. Visualization of the proteins was performed 
by using Zeiss LSM 510 Meta Confocal Microscope (Zeiss, Oberkochen, Germany). 
 
Western blot 
Cells were harvested and homogenized in protease inhibitor cocktail (1:100; Sigma-Aldrich) 
containing detergent mixture (50 mM TRIS HCl, 150 mM NaCl, 1% Triton X-100, 1% Igepal 
CA 630, 0.5% sodium deoxicholate; Sigma-Aldrich). Protein concentrations were determined 
by using BCA reagent (Pierce, Rockford, IL, USA) and set to 0.5 µg/ml. Equal amount of 
protein samples (5 µg/well) were subjected to SDS-PAGE (10% Mini Protean TGX gels, 
BioRad, Hercules, CA, USA), and transferred to nitrocellulose membranes, by using Trans-
Blot® Turbo™ Nitrocellulose Transfer Packs and Trans Blot Turbo System (both from 
BioRad). Membranes were probed with the corresponding primary antibodies overnight at 4°C. 
We applied anti-human TRPV1, TRPV2, TRPV4 (1:100) and TRPV3 (1:200) antibodies, 
diluted in 5% milk containing PBS. As secondary antibodies, horseradish peroxidase-
conjugated rabbit anti-goat and goat anti-rabbit IgGs (1:1000, BioRad) were applied and the 
immunoreactive bands were visualized by a SuperSignal West Pico Chemiluminescent 
Substrate-Enhanced Chemiluminescence kit (Pierce) using Gel Logic 1500 Imaging System 
(Kodak, Tokyo, Japan). To assess equal amount of protein in the different samples, we detected 
β-actin as control using rabbit anti-human β-actin antibody (1:1000, Sigma-Aldrich). 
 
Transient overexpression of human recombinant TRPV channels 
To check the specificity of the antibodies used in western blot experiments, we transiently 
overexpressed human recombinant TRPV1-4 proteins in HEK293T cells and subjected the cell 
lysates to western blot. HEK293T cells cultured in 96 mm Petri dishes were transfected at 50-
60% confluency using TransIT-293 Transfection Reagent (MirusBio, Madison, WI, USA). 36 
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l TransIT-293 reagent and 12 l DNA construct were gently mixed in 600 l OptiMEM 
(LifeTechnologies) medium, incubated for ca. 20 min and added to the cell cultures drop by 
drop. Following an incubation for additional 48 hrs, cells were harvested and subjected for 
western blot analysis as described above. As DNA constructs, sequence of human TRPV1 was 
cloned in the pCAGGSM2-IRES-GFP-R1R2 vector and sequences of human TRPV2, TRPV3 
and TRPV4 isoforms were cloned in the pCINeoIRES-GFP vector. The constructs were 
provided by Prof. Thomas Voets (Laboraory of Ion Channel Research, KU Leuven, Leuven, 
Belgium). 
 
Gene silencing by RNA interference (RNAi) 
Human podocytes were seeded in small Petri dishes or in 96-well black-wall/clear-bottom 
plates (Greiner Bio-One, Kremsmuenster, Austria) suitable for fluorescent measurements in 
culture medium. After the podocytes’ differentiation, medium was changed to fresh culture 
medium and cells were transfected with siRNA oligonucleotides targeting human TRPV3 
(Stealth RNAi, Invitrogene, ID: HSS136315) using Lipofectamine™ RNAiMAX Transfection 
Reagent and serum-free Optimem (both from Invitrogen). For controls, siRNA Negative 
Control Duplexes (scrambled RNA, Invitrogen) were employed. 48 hours after transfection 
cells in Petri dishes were harvested to quantitatively evaluate the efficacy of siRNA-driven 
silencing by Q-PCR and flourescent Ca-measurements were performed on cells seeded in 
microplates. 
 
Quantitative Real-Time PCR (Q-PCR) 
To determine the quantitative expressions of various TRPs at the mRNA level, Q-PCR was 
performed on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, 
CA, USA) using the 5’ nuclease assay. Total RNA was isolated using TRIzol (Invitrogen) and 
reverse-transcribed into cDNA using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) and then amplified on a GeneAmp PCR System 2400 DNA Thermal Cycler 
(Applied Biosystems). PCR amplification was performed by using TaqMan primers and probes 
(assay ID-s: Hs00218912_m1 for TRPV1, Hs00275032_m1 for TRPV2, Hs00376854_m1 for 
TRPV3 and Hs00222101_m1 for TRPV4; all from Applied Biosystems). As internal controls, 
transcripts of peptidylprolyl isomerase A (PPIA; assay ID: Hs99999904_m1), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; assay ID: Hs99999905_m1) and β-actin (ACTB; assay 
  
This article is protected by copyright. All rights reserved. 
ID: Hs99999903_m1) were determined (all from Applied Biosystems). During the analysis we 
used the geometric mean of the PPIA, GAPDH and ACTB as reference value. 
 
Fluorescent Ca2+ measurements 
Fluorescent measurement of cytoplasmic Ca2+ concentration was performed by according to 
our previously optimized protocol: human podocytes were seeded in 96-well/clear-bottom 
plates (Greiner Bio-One) at a density of 20,000 cells per well in podocyte medium and cultured 
at “non-permissive” conditions for 7 days. On the 7th day the cells were washed once with 
Hank’s solution (“normal buffer”: 136.8 mM NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4, 0.44 
mM KH2PO4, 0.81 mM MgSO4, 1.26 mM CaCl2, 5.56 mM glucose, 4.17 mM NaHCO3, pH 
7.2, all from Sigma-Aldrich) containing 1% bovine serum albumin and 2.5 mM Probenecid 
(both from Sigma-Aldrich) than loaded with 1 μM Fluo-4 AM (Life Technologies Corporation, 
Carlsbad, CA, USA) dissolved in Hank’s solution (100 μl/well) at 37°C for 30 min. The cells 
were washed three times with Ca2+-containing (normal buffer) or Ca2+-free (Ca2+-free buffer) 
Hank’s solution (100 μl/well). In the Ca2+-free buffer, equimolar glucose substituted for CaCl2. 
The plates were then placed into a FlexStation 3 fluorescent microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) and cytoplasmic Ca2+ concentration (reflected by fluorescence; 
λEX: 494 nm, λEM: 516 nm) was monitored during application of compounds in various 
concentrations. During the measurements, cells in a given well were exposed to only one given 
concentration of the agents. When applying antagonists, cells were pretreated for 30 min and 
the measurements were carried out in the continuous presence of fixed concentration of the 
applied antagonist. Experiments were performed in multiple wells and cells in different wells 
were cultured, differentiated and treated individually and independently. Data are presented as 
F1/F0, where F0 is the average fluorescence of the baseline (before compound application) and 
F1 is the actual fluorescence. During data analysis, n represents individual, independently 
measured wells.  
To investigate the effect of a heat pulse on intracellular Ca2+ concentration, podocytes were 
seeded and differentiated in 35 mm diameter Petri dishes and loaded with 1 μM Fluo-4 AM 
(Life Technologies). Then, Petri dishes containing 300 l ambient temperature normal buffer 
were placed on the stage of an Olympus IX83 inverted fluorescent microscope (Olympus, 
Tokyo, Japan) and fluo-4 loaded cells were imaged with constant settings in every 9 s, using 
the autofocus mode between each capturing. During measurement, 1 ml pre-heated solution 
was pipetted into the petri dishes. Images were captured using an Xcellence Pro live cell 
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imaging system (Olympus) and analysed in Fiji app running ImageJ software (Schindelin et 
al., 2012, 2015). 
 
Patch clamp recording 
Podocytes were seeded in small Petri dishes and whole cell patch clamp measurements were 
made by using an Axopatch 1.D amplifier and Clampex 10.2 software (Molecular Devices) on 
the next day. To record GSK evoked transmembrane currents, experiments were performed in 
a bath solution containing 150 mM NaCl, 6 mM CsCl, 5 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES and 10 mM glucose buffered to pH 7.4 (NaOH), whereas the pipette solution consisted 
of 100 mM aspartic acid, 20 mM CsCl, 1 mM MgCl2, 0.08 mM CaCl2, 4 mM Na2ATP, 10 
mM EGTA, 10 mM HEPES and pH was set to 7.2 using CsOH resulted in ca. 100 mM CsAsp 
in the final pipette solution. The holding potential was 0 mV and cells were ramped every 2 s 
from −120 to +100 mV over the course of 400 ms. 
 
Curve fitting 
Logistic dose-response curves were fitted using the equation y = A2 + (A1-A2)/(1 + (x/x0)^p) 
where the calculated parameters are: A1: initial value (ymin), A2: final value (ymax), x0: center 
(EC50) and p is the calculated power. Fittings were carried out and parameters were calculated 
using Origin 9.0 (OriginLab Corporation, Northampton, MA, USA). 
 
Data and statistical analysis 
Since the experiments were carried out on cell cultures using objective methods resulting in 
quantitative, interval scale numeric data which were analyzed by properly chosen statistical 
methods, we did not count with any influence of the experimenter expectation on the results. 
Therefore, no randomization and blinding was performed. If it is not mentioned otherwise, data 
are presented as mean ± SEM. Normality of data was tested by Shapiro-Wilk test in each group. 
Comparison of means between multiple groups was done by One-Way ANOVA. If F achieved 
P<0.05, pairwise comparison was done by appropriate post-hoc tests. Homogeneity of 
variances was tested by Levene’s test. If no inhomogeneity was found, ANOVA was followed 
by either Dunnett or Bonferroni post-hoc tests, as appropriate. In case of inhomogeneous 
variances, Dunnett’s T3 test was performed. To compare means of two groups with data not 
passing normality, Mann-Whitney U-test was performed. In every case, p<0.05 values were 
regarded as significant differences. All statistical analysis was performed using IBM SPSS 
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Statistics 23.0 (IBM, Armonk, NY, USA). The data and statistical analysis comply with the 
recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015). 
 
Materials 
Capsaicin, capsazepine, eugenol, carvacrol, thymol, 2-Aminoethoxydiphenyl borate (2-APB), 
4α-Phorbol 12,13-didecanoate (4α-PDD) and GSK1016790A were obtained from Sigma-
Aldrich. AMG 9810, cannabidiol (CBD) and HC067047 were purchased from Tocris 
Bioscience (Bristol, UK) and resiniferatoxin (RTX) from Santa Cruz (Santa Cruz, CA, USA). 
Tranilast was bought from Cayman Chemical Company (Ann Arbor, MI, USA). Isopentenyl 
diphosphate (IPP) was from Echelon Biosciences (Salt Lake City, UT, USA). Ruthenium red 
was obtained from Research Biochemicals International (Natick, MA, USA). 
 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
 
Results 
First, we investigated the molecular expression of heat sensitive TRPV1-4 channels in 
cultured, differentiated human podocytes. Immunocytochemical staining revealed a general 
expression of all the investigated proteins in differentiated human podocytes, although the 
TRPV1 staining showed a relatively weaker signal compared to TRPV2-4 (Figure 1A). For 
western blot, we have used selected antibodies of which specificity we have checked by 
probing human recombinant TRPV1-4 overexpressed in human embryonic kidney derived 
(HEK293T) cell line (Supplementary figure 1.). The selected antibodies detected all the 
investigated TRPV isoforms both in differentiated and non-differentiated podocytes, although 
the molecular weight of the detected bands was not fully identical with the size of the bands 
detected in the recombinant cell line (Figure 1B). The podocytes specific TRPV1 and TRPV2 
bands were detected at a minimal higher molecular weight. The specific antibody detected 
multiple bands of the recombinant TRPV3 among which only one (ca. 60 kDa) was detected 
in podocytes. Interestingly, the TRPV4 specific antibody detected a very clear single band 
corresponding to the predicted molecular weight of the TRPV4 in HEK293T cells 
overexpressing the recombinant channel. However in podocytes, we could detect very intense 
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signals, but at definitely lower molecular weight. Nevertheless, each protein was detected both 
in differentiated and undifferentiated cells, as well. Generally, the intensity of all the TRPV1-
4 immunoreactivity was found to be decreased in differentiated podocytes compared to 
undifferentiated cells. To further assess the quantitative expression of TRPV channels 
compared to each other, we studied the expression of specific TRPV transcripts by Q-PCR. We 
found that the expression of TRPV1 and TRPV4 was relatively high, but TRPV2 and TRPV3 
were expressed at relatively low levels (Figure 1C). 
Since the molecular expression studies revealed a general expression of heat sensitive 
TRPV channels, we investigated the functional responses for a thermal challenge applying a 
heat pulse by adding pre-warmed buffer to differentiated podocyte cultures. Since the studied 
channels are Ca2+-permeable ones, their activity was investigated by monitoring the 
intracellular Ca2+ concentration using the fluorescent Ca2+-sensitive reporter dye Fluo-4 upon 
heat stimulation. The majority of the cells reacted for the heat pulse with a transient elevation 
of the intracellular Ca2+ concentration (Figure 1D-F, Supplementary video 1-2) which response 
was not seen upon applying ambient temperature as a stimulus (Figure 1F and Supplementary 
video 3). These results clearly indicated the presence of heat sensitive Ca2+ channels in 
differentiated human podocytes. However, the applied heat pulse protocol was not specific 
enough to identify the individual heat sensitive channels and discriminate between the 
contributions of the different TRPV isoforms which can bare partially overlapping temperature 
sensitivity in various conditions. Therefore, to judge the functionality of the individual TRPV 
isoforms, we used various pharmacological tools to activate these channels and assessed their 
specificity by applying specific antagonist pretreatments, if specific antagonists were available. 
Capsaicin, a specific, potent activator of TRPV1 (Caterina et al., 1997), did not induce 
any remarkable alteration in the intracellular Ca2+ concentration of the podocytes up to 1 mM. 
The presence of TRPV1 specific antagonists capsazepine or AMG 9810 did not influenced the 
lack of the capsaicin effect (Figure 2A-B). Similarly, the ultrapotent TRPV1 agonist RTX also 
failed to evoke any response (Figure 2C). These results suggested, that TRPV1, in spite of the 
relatively high expression of the mRNA transcripts, does not form a functional channel in the 
cultured, differentiated human podocytes. 
The phytocannabinoid cannabidiol, an agonist of both TRPV2 (Qin et al., 2008) and 
TRPV4 (De Petrocellis et al., 2012), induced a moderate elevation of intracellular Ca2+ 
concentration when applied at ≥10 µM concentration (EC50=10.56±1.28µM – Figure 3.). This 
effect was mainly eliminated by omitting the Ca2+ from the extracellular solution suggesting 
that cannabidiol activated Ca2+-permeable ion channels in the plasma membrane. The presence 
  
This article is protected by copyright. All rights reserved. 
of 75 µM tranilast (Nie et al., 1997), a potent ion channel inhibitor recently used targeting 
TRPV2 (Hisanaga et al., 2009; Mihara et al., 2010; Perálvarez-Marín et al., 2013), effectively 
inhibited the cannabidiol induced Ca2+ signals suggesting the presence of functionally active 
TRPV2 channels. However, cannabidiol was also reported as a weak agonist of TRPV4 (De 
Petrocellis et al., 2012). Therefore, we investigate the involvement of TRPV4 in the 
cannabidiol induced Ca2+ signals and we repeated the experiments in the presence of 
HC067047, a potent and selective blocker of TRPV4 (Everaerts et al., 2010). 1 µM HC067047 
inhibited the cannabidiol induced Ca2+ responses ca. as effectively, as tranilast did (Figure 3.), 
further confirming our previous results that cannabidiol can activate TRPV4 (Oláh et al., 2014) 
and suggesting the presence of functional TRPV4 channels in human podocytes. 
To further dissect the functionality of TRPV4, we investigated the effect of the hyper-
potent TRPV4 agonist, GSK1016790A (Thorneloe et al., 2008) on the intracellular Ca2+ 
concentration of podocytes. We found that GSK1016790A applied at nM concentration 
induced a rapid and robust elevation of intracellular Ca2+ concentration which was strongly 
inhibited by the TRPV4 selective blocker, HC067047 (EC50s were found 3.63±0.33 and 
57.07±6.02 nM in the absence and presence of 1 µM HC067047, respectively - Figure 4A-B). 
Not only the peak, but also the slope of the Ca2+-transients increased dose-dependently by 
GSK1016790A in Ca2+ containing buffer even after the saturation of the Ca2+ signals clearly 
indicating higher open probability of plasma membrane located TRPV4 channels (Figure 4C-
D). GSK1016790A was found to be able to elevate the intracellular Ca2+ even in the absence 
of extracellular Ca2+, although it was less potent (EC50=10.04±0.72 nM) and definitely slower 
than in normal, Ca2+ buffer (Figure 4A-D), suggesting that functional TRPV4 channels are 
expressed on the intracellular Ca2+ stores, as well. However the much steeper rising phase in 
the presence of extracellular Ca2+ suggested that the majority of the channels are activated by 
the agonist in the plasma membrane (Figure 4D). The classical TRPV4 agonist 4α-PDD 
(Watanabe et al., 2002) also evoked an elevation in the intracellular Ca2+ concentration 
(EC50=0.52±0.06 M) and its effect was also inhibited by HC067047, although 4α-PDD was 
found less effective than GSK1016790A (Figure 4E-F). 4α-PDD evoked responses were 
abolished in the absence of extracellular Ca2+ suggesting again that the majority of the activated 
TRPV4 channels are located in the plasma membrane. This was also supported by whole cell 
patch clamp experiments in which we have detected strong GSK1016790A induced 
transmembrane currents which biophysical characteristic corresponded to TRPV4. Similarly 
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to the Ca2+ signals, GSK1016790A induced transmembrane currents were also inhibited by 
HC067047 (Figure 4G-H). 
Since specific agonist and antagonists are not available commercially, the 
pharmacological identification and separation of TRPV3 is the most challenging among heat 
sensitive TRPV channels. Although they lack specificity, several herbal compounds, like 
eugenol, thymol or carvacrol, are reported as potent TRPV3 activators (Xu et al., 2006; Vriens 
et al., 2008). Probing these compounds on differentiated human podocytes we found a marked 
activation in the concentration range reported for effective activation of TRPV3 (Xu et al., 
2006; Vriens et al., 2008), suggesting the presence of functional TRPV3 on human podocytes 
(Figure 5A-B.). However, the dose-response relationships were not saturated up to 1.5 mM and 
did not show sigmoid shape, suggesting that these compounds can activate other targets on 
podocytes, as well. In contrast, application of 2-APB, a synthetic but also not specific activator 
of TRPV3 (Chung et al., 2004; Vriens et al., 2009), significantly elevated cytoplasmic Ca2+ 
concentration from extracellular source resulting in a sigmoidal dose-response relationship 
(EC50=499.51±51.166 µM) (Figure 5C-D). Although the above compounds are effective 
activators of TRPV3, all of them lack specificity and can affect cytoplasmic Ca2+ concentration 
via several other targets including other TRP channels, store operated Ca2+ entry or inositol 
trisphosphate (IP3) receptors. Selected concentrations of carvacrol, thymol and 2-APB were 
only partially inhibited by the general, non-specific TRP channel inhibitor ruthenium red 
(≤35% inhibition); likewise, the endogenous TRPV3 inhibitor IPP (Bang et al., 2011) partially 
inhibited only the 2-APB induced Ca2+ transients (~23% inhibition) (Figure 5E). Transfection 
of the podocytes with siRNA targeting TRPV3 resulted in a marked decrease in the expression 
of the channel compared to the scrambled RNA transfected control cells (Figure 5F). Although 
the TRPV3 silencing was found effective, it does not influenced the Ca2+ responses evoked by 
the above agonists. These results indicate that although TRPV3 activators were effective in 
increasing cytoplasmic Ca2+ concentration of differentiated human podocytes, their application 
likely evokes several off-target effects and the contribution of TRPV3 to these Ca2+ responses 
is minimal. 
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Discussion 
In our current study, we provided the first evidence for the functional expression of the 
heat sensitive members of the vanilloid subfamily of TRP channels in human podocytes. We 
described heat evoked Ca2+ signals and detected the presence of TRPV1, 2, 3 and 4 proteins in 
the investigated conditionally immortalized human podocyte cell line. However, native TRPV3 
and TRPV4 were detected at lower molecular weight in podocytes compared to the 
recombinant channels, which might suggest different degradation of these channels in the two 
cell lines. Quantitative analysis of the mRNA transcripts revealed that TRPV1 and TRPV4 are 
the dominantly expressed TRPV channels but TRPV2 and TRPV3 were also detected at lower 
levels. These findings are highly consistent with publicly available microarray data of Da Sacco 
et al., (2013) (GEO Series accession number: GSE49439). Moreover, an additional 
transcriptome analysis (Boerries et al., 2013) also detected TRPV1-4 transcripts in primary 
isolated mouse podocytes. 
Dissecting the functionality of TRPVs, we surprisingly found that TRPV1 specific 
agonist capsaicin and the ultrapotent agonist RTX failed to induce significant Ca2+ entry to 
podocytes suggesting loss of vanilloid sensitivity or an impaired functionality of TRPV1 in the 
investigated cell line. TRPV1, earlier assigned as capsaicin-receptor, is robustly activated by 
capsaicin in human and rodents, however TRPV1 was found insensitive for capsaicin in several 
other species (Jordt and Julius, 2002; Gavva et al., 2004). Recent research revealed the 
molecular mechanism of capsaicin binding to TRPV1 and identified key amino acid residues 
in which mutations decreased capsaicin sensitivity (Yang et al., 2015). Single nucleotide 
polymorphisms in the human TRPV1 are also known to be associated with lowered capsaicin 
sensitivity (Cantero-Recasens et al., 2010). Moreover, a capsaicin insensitive splice variant 
TRPV1b was identified and its expression was reported in trigeminal and dorsal root ganglia 
(Lu et al., 2005; Charrua et al., 2008; Mistry et al., 2014) and in keratinocytes (Pecze et al., 
2008). If TRPV1b is co-expressed with TRPV1 it behaves as dominant negative subunit 
disrupting capsaicin/vanilloid sensitivity of the channel (Vos et al., 2006). In our case, both 
mutations in the key residues or the presence of the dominant negative subunit TRPV1b can be 
a rational explanation for the finding that in spite of the molecular expression of TRPV1, we 
did not find any functional effect of capsaicin. Although desensitization by signaling pathways 
or functional inhibition by interacting partners, e.g. phosphoinositols (Planells-Cases et al., 
2011; Rohacs, 2015), may also decrease the capsaicin sensitivity of TRPV1, further studies are 
needed to identify the contribution of the different potential mechanisms. 
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In contrast to TRPV1, TRPV2 was detected not only at molecular level, but the presence 
of functional TRPV2 channels in the membrane of cultured human podocytes is strongly 
supported by our results showing that TRPV2 agonist CBD induced a calcium influx from the 
extracellular space which was inhibited by tranilast, a suggested antagonist of TRPV2. 
However, the specific TRPV4 blocker HC067047 also effectively inhibited CBD induced Ca2+ 
entry; therefore we concluded that functional TRPV4 channels can also be involved in the 
effect of CBD. Indeed, the classical TRPV4 agonist 4-αPDD and the ultrapotent 
GSK1016790A induced a fast and robust increase in the cytoplasmic Ca2+ concentration which 
was strongly inhibited in the presence of the antagonist HC067047. In podocytes, 
GSK1016790A also induced marked transmembrane currents with a voltage dependence 
characteristic for TRPV4 (Jin et al., 2011) and blocked by HC067047. These functional results 
suggest that, in good accordance with the molecular expression data, TRPV4 is the dominantly 
expressed thermosensitive TRPV channel in human podocytes.  
In contrast to TRPV4, the functional presence of TRPV3 is ambiguous. Although we 
identified the presence of TRPV3 proteins, quantitative analysis of expression of TRPV3 
transcripts suggested a relatively low expression level compared to TRPV4. The 
pharmacological identification is uncertain since we lack commercially available, effective and 
highly specific TRPV3 agonists and antagonists. The botanical compounds carvacrol, thymol 
and eugenol, as well as the synthetic 2-APB used in our experiments are potent, but highly 
unspecific agonists generally used to study TRPV3 functions (Chung et al., 2004; Xu et al., 
2006; Vriens et al., 2008, 2009). In human podocytes, all the above compounds evoked marked 
elevation of the cytoplasmic Ca2+ concentration, which source was mainly the extracellular 
space (at least if compounds were applied at concentrations ≤1 mM), but only the effect of 2-
APB was saturated in the concentration range applied making possible the correct fitting of a 
sigmoidal dose-response curve. The experimentally determined EC50 (~500 µM) was higher, 
than found earlier in electrophysiological studies on recombinant TRPV3 (~42 µM at 
physiological membrane potential - Chung et al., 2004). Moreover, the general TRP channel 
blocker ruthenium red (Alexander et al., 2015) could only partially block the effect of the 
compounds and the endogenous TRPV3 inhibitor IPP was effective partially blocking only 2-
APB evoked Ca2+ signals. In contrast, RNAi mediated silencing of the molecular expression 
of TRPV3 did not influenced the effect of the agonists. All this results argue for manifest off-
target effects of the TRPV3 ligands which can include the activation of several other TRP 
channels, and numerous other targets involved in cellular Ca2+ handling, like IP3 receptors, 
ryanodine receptors, sarcoplasmic reticulum Ca2+-ATPase or store operated Ca2+ entry 
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mechanisms (Chung et al., 2004; Xu et al., 2006; Sárközi et al., 2007; Vriens et al., 2008, 2009; 
Hsu et al., 2011; Liang and Lu, 2012). Therefore, although our results suggest that TRPV3 is 
expressed in human podocytes, its functionality is not clear. The exact role of TRPV3 in the 
Ca2+ signals evoked by its activators needs further investigations. However, more specific 
pharmacological tools hopefully available in the near future are desired to validate our results 
and further dissect the potential role of TRPV3 in podocytes. 
The expression of heat and mechanosensitive TRPV channels has been already being 
investigated in the lower urinary tract and in the kidney since their cloning (Hayes et al., 2000; 
Strotmann et al., 2000; Kassmann et al., 2013). Although clear evidences support the role of 
TRPV1 in the control of lower urinary tract functions, its expression in urothelial cells is still 
under debate (for a review see: Franken et al., 2014). TRPV4 is more abundantly expressed in 
the non-neural cells of the urinary tract. In the kidney, TRPV4 expression was found overall in 
the constitutively water impermeable segments of the nephron (thin and thick ascending limb, 
distal convoluted tubule) and in the collecting ducts, as well (Tian et al., 2004). Moreover, both 
TRPV1 and TRPV4 were described to form functionally active channels in the endothelium of 
the renal vasculature (Chen et al., 2015). 
Although the expression of heat sensitive TRPV channels is known in the kidney, we 
lack the complete understanding of their functions in the different segments of the tubular 
epithelium, and we especially lack any data regarding podocytes. Although actually we do not 
have data about the physiological role of TRPV1-4 in regulating cellular functions of 
podocytes, it is well known, that Ca2+ signaling related to other TRP channels, namely TRPC6 
and TRPC5, have a crucial impact on podocytes’ biological functions influencing cytoskeletal 
rearrangements and consequently the physical characteristic of the slit diaphragm and the 
filtration barrier. Interestingly, TRPC5 and TRPC6 seem to oppositely regulate podocyte actin 
dynamics and cell motility via RhoA and Rac1, respectively (Tian et al., 2010; Schaldecker et 
al., 2013; Tian and Ishibe, 2016). Moreover, a recent study suggested that wild type TRPC6, 
but not the mutant allele TRPC6-N143S, originally described in a family with FSGS, showed 
intrinsic mechanosensitivity and responded to hypotonic challenges (Wilson and Dryer, 2014) 
suggesting a potential role of osmotic stimuli and consequent (TRP mediated) Ca2+ signals in 
the regulation of podocytes’ functions. 
In the renal tubular system, an important role in transmitting the effect of tubular flow 
and osmolarity is attributed to TRPV4 (Mamenko et al., 2015). TRPV4 mediated flow-induced 
increases in intracellular Ca2+ concentration in medullary thick ascending limbs (Cabral et al., 
2015) and its role was revealed in hypotonic stimuli induced Ca2+ entry needed for regulatory 
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volume decrease in renal cortical collecting duct cells (Galizia et al., 2012). Beyond 
osmosensation, TRPV4 seems to play an emerging role in the formation of epithelial barrier in 
several tissues. In airway epithelium, sheer stress enhanced epithelial barrier function via serial 
activation of TRPV4 and voltage gated L-type Ca2+ channels (Sidhaye et al., 2008). In 
epidermal keratinocytes of the skin, functionally active TRPV4 channels were found to interact 
with adherent junction proteins and actin cytoskeleton, enhancing cell-cell junction and tight 
barrier formation. In this process TRPV4 contributed to the elevation of intracellular Ca2+ 
concentration resulting in small GTPase Rho activation and consequent actin rearrangement. 
Moreover, its pharmacological activation augmented tight junction development and barrier 
recovery (Sokabe et al., 2010; Kida et al., 2012; Akazawa et al., 2013). Most recently, TRPV4 
was described in bladder urothelium and kidney collecting duct epithelium associating with 
adherent junctions directly interacting with junctional proteins, especially α-catenin, an 
intracellular adherent junction protein connected to the actin cytoskeleton (Janssen et al., 2016). 
All these data further suggest a putative contribution of TRPV4 to the fine orchestration of 
podocytes Ca2+ homeostasis regulating the filtration barrier. 
Since podocytes in the outermost layer of the glomeruli form the final barrier to protein 
loss, their injury is often associated with marked proteinuria syndromes (Somlo and Mundel, 
2000). Distinct diseases, like diabetic nephropathy, hypertension, as well as inherited or drug-
induced podocytopathies can results in disruption of the slit diaphragm leading to proteinuria 
(Mathieson, 2011).. Although the detailed pathomechanism is still unknown, cytoskeletal 
disorganization as a consequence of the altered Ca2+ signaling can be an important step. 
Although the potential role of TRPV channels has not been investigated yet, numerous studies 
suggested the role of several elements of the cellular Ca2+ signaling pathways like TRPC6 or 
angiotensin II receptor related pathways (Wieder and Greka, 2016). The activity of the TRPV 
channels, especially TRPV4, can be affected directly by the altered, disease associated physical 
environment like increased flow and shear stress or altered osmotic concentrations, as detailed 
above. However, TRPV4 can be modulated by intracellular signaling pathways, among else, 
by angiotensin II signaling (Shukla et al., 2010; Tajada et al., 2017) which is of particular 
importance in podocytes (Hoffmann et al., 2004). These potential integrative role of the 
TRPV(4) channels can make them especially appealing targets for future drug developments 
in various forms of podocyte associated diseases.  
All in all, although further studies are needed to clarify the potential role of TRPV 
channels in podocyte (patho)physiology, detailed understanding of their pharmacological role 
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in physiological and disease conditions might contribute to the development of future therapies 
of primary and secondary podocytopathies and related kidney diseases.  
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Figure 1: 
Expression of thermosensitive transient receptor potential vanilloid 1-4 (TRPV1-4) channels 
in differentiated human podocytes. (A) TRPV1-4 immunoreactivity were determined on 
differentiated human podocyte cultures by fluorescent labeling (Alexa-Fluor®-488, green 
fluorescence). Nuclei were counterstained with DAPI (blue fluorescence). Calibration mark: 
50 μm. (B) Lysates of non-differentiated (nDif) and differentiated (Dif) human podocytes were 
subjected to western blot analysis and immunolabeled with specific TRPV antibodies. To 
assess equal loading of protein samples, expression of β-actin was determined. MW indicates 
molecular weight in kDa. (C) Expression of TRPV1-4 mRNA transcripts were detected by Q-
PCR in non-differentiated and differentiated human podocytes. Expression of peptidylprolyl 
isomerase A (cyclophilin A; PPIA), β-actin (ACTB) and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were determined and the geometrical mean of their expression was 
used as internal control for normalization. Data are expressed as mean ± SEM, n=3 independent 
determinations. (D) Representative images illustrating the effect of a heat pulse on 
differentiated podocytes. Cells were uploaded with the fluorescent Ca2+ sensitive dye Fluo-4 
and challenged to a heat pulse as described in the ‘Materials and methods’. Arrowheads 
indicate representative cells displaying increase in intracellular Ca2+ concentration upon heat 
stimulation. (E) Representative Ca2+ traces obtained from the experiment shown in panel (D). 
The colors of the traces correspond to the colors of the arrowheads in panel (D). (F) Changes 
in intracellular Ca2+ concentration in differentiated podocytes upon control and heat pulse 
stimulations. Markings of the box plot represents 25-50-75 percentile of the cells, thick line 
and whiskers indicate the mean and ±1 SD of the maximal Ca2+ signals, respectively. * 
indicates significant difference between the groups as determined by Mann-Whitney U-test, 
p<0.05. 
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Figure 2: 
Effect of TRPV1 ligands on the intracellular Ca2+ concentration of differentiated human 
podocytes. (A) Representative time curses of capsaicin application in various conditions. Cells 
were preincubated with capsazepine and AMG 9810 for 30 minutes and constant 
concentrations of the antagonists were presented as indicated on the figure continuously during 
the measurements. (B) Dose-response relationship of capsaicin in various conditions as 
indicated. The measurements were carried out as in panel A. Data are presented as mean ± 
SEM, n=6 in each group. (C) Dose-response relationship of RTX in normal and Ca2+-free 
buffer. The measurements were carried out as in panel A, but RTX was applied instead of 
capsaicin. Data are presented as mean ± SEM, n=5 in each group. 
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Figure 3: 
Effect of CBD on the intracellular Ca2+ concentration of differentiated human podocytes. (A) 
Representative time curses of CBD applications in various conditions. Cells were preincubated 
with tranilast and HC067047 for 30 minutes and measurements were carried out in the 
continuous presence of constant antagonist concentrations as indicated on the figure. (B) Dose-
response relationship of CBD in various conditions as indicated. The measurements were 
carried out as in panel A. Data are presented as mean ± SEM, n=6 in each group. Logistic dose-
response curve fitting was carried out as described in the ‘Materials and methods’. * indicates 
significant activation by CBD compared to the vehicle (0 µM CBD) control. # indicates 
significant inhibition by 75 µM tranilast. $ indicates significant inhibition by 1 µM HC067047. 
P<0.05 in each case. 
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Figure 4: 
Activation of TRPV4 in differentiated human podocytes. (A) Representative time courses of 
TRPV4 agonist GSK1016790A applications in different conditions. Cells were preincubated 
with HC067047 for 30 minutes and measurements were carried out in the continuous presence 
of constant antagonist concentrations as indicated on the figure. (B) Dose-response relationship 
of GSK1016790A in various conditions as indicated in the legend. Measurements were carried 
out as shown in panel A. Data are presented as mean ± SEM, n=6 in each group. Logistic dose-
response curve was fitted as described in the ‘Materials and methods’ assuming equal efficacy 
(i.e. equal maximal responses available) in each condition. (C) Representative time courses 
upon application of various concentration of GSK1016790A in normal buffer illustrating the 
concentration dependence of the slope of the Ca2+ transients. (D) Concentration dependence of 
the maximal slope of the Ca2+ transients upon GSK1016790A application, n=6 in each group. 
(E) Dose-response relationship of 4-αPDD in various conditions as indicated in the legend. 
Measurements were carried out as shown in panel A, but 4- αPDD was used instead of 
GSK1016790A. Data are presented as mean ± SEM, n=5 in each group. Logistic dose-response 
curve was fitted as described in the ‘Materials and methods’. (F) Concentration dependence of 
the maximal slope of the Ca2+ signals upon 4-αPDD application, n=5 in each group. (G) 
Representative time courses illustrating the effect of GSK1016790A and HC067047 on 
transmembrane currents of podocytes measured at -80 and +80 mV. A voltage ramp from -120 
to +100 mV was applied at every 2 s as described in the ‘Materials and methods’. (F) I-V 
relationship of the transmembrane currents at different time points as indicated in panel (E). In 
(B), (D), (E) and (F), * indicates significant activation by GSK1016790A compared to the 
vehicle (0 nM GSK1016790A) control in the same conditions. # indicates significant inhibition 
by 1 µM HC067047. P<0.05 in each case. 
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Figure 5: 
Effect of TRPV3 activators on the intracellular Ca2+ concentration of differentiated human 
podocytes. (A) Representative time courses showing the application of TRPV3 activator herbal 
compounds on differentiated human podocytes in normal buffer. Activators and ATP as 
positive control were applied as shown in the figure. (B) Dose-response relationship of 
carvacrol, thymol and eugenol in normal and Ca2+-free buffer. Measurements were carried out 
as shown in panel A. (C) Representative time courses showing the effect of 2-APB on 
differentiated human podocytes in normal and Ca2+-free buffer. (D) Dose-response relationship 
of 2-APB treatment as shown in panel C. (B) and (D) Data are presented as mean ± SEM, n=6 
in each group. * indicates significant activation by the compound marked with the 
corresponding color compared to the vehicle (0 µM compound) in normal buffer, p<0.05. (E) 
Effect of potential TRPV3 inhibitors ruthenium red (RR) and IPP on selected concentrations 
of carvacrol, thymol and 2-APB as indicated. Mean ± SEM data are presented as percent of the 
average of the corresponding control (i.e. agonist application in the absence of the antagonist). 
This normalization was performed to control the variance of the effectivity between different 
agonists and make comparable the inhibition evoked by the antagonists in the different groups. 
Response was calculated as the maximal amplitude (max. F1/F0-1) of the Ca
2+ transients during 
the agonist application. Cells were pretreated with the inhibitors for 30 min before the agonist 
application and the whole experiment was carried out in the continuous presence of the 
inhibitors in fixed concentration. Data are presented as mean ± SEM, n=6 in each group. * 
indicates significant (p<0.05) inhibition by IPP or ruthenium red as indicated. Statistics were 
calculated with the raw data using ANOVA and Dunnett post-hoc test. (F) Changes in the 
expression of TRPV3 mRNA transcripts 48 hours following transfection with either non-
coding, scramled RNA (scr-RNA) or siRNA targeting TRPV3 (siRNA). Data are normalized 
to the average of the untransfected control to indicate the fold change in the TRPV3 expression. 
Normalized data are presented as mean ± SEM of three independent determination. (G) Effect 
of siRNA transfection targeting TRPV3 on the Ca2+ signals evoked by the indicated agonists. 
Measurements were carried out at 48 hours after transfection. Averages of the corresponding 
control treatments on scrambled RNA transfected cells are considered as 100% in each case to 
control the variance of the effectivity between different agonists and make comparable the 
effect of the siRNA transfection in the different groups. Data are presented as mean ± SEM, 
n=6 in each group. 
 
